Search
Login
My Portfolios Login
TradeMachine® Login
CML Research Pro Login
Get TradeMachine®
Get CML Research
Compare Products
Home
My Portfolios
CMLViz News
Breaking
Stock
Scanner
Tear Sheet
News
Profile
Stats
Stock Chart
Pivot Points
Financial Charts
Holders
Analysts
Day Trader
Back-Tester
SPX
3,825.33
+40.17
(
+1.05%
)
Dow 30
+1.00%
QQQ
+0.66%
VIX
26.7
-2.01
(
-7.00%
)
Vertex Pharmaceuticals, Inc.
NASDAQ:VRTX
287.24
+5.45
(
+1.93%
)
Products
Vertex Pharmaceuticals Announces Inaxaplin Granted Breakthrough Therapy Designation By U.S. FDA And Priority Medicines (Prime) Designation By The EMA
Published: 06/08/2022 13:15 GMT
VRTX
Vertex Pharmaceuticals, Inc. (
VRTX
)
- Vertex Announces Inaxaplin (vx-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (prime) Designation by the Ema.